Trial · NCT01097044
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time in Direct Sunlight Between 10:00-15:00 on Pain-free Days | Afamelanotide | 8.25 | Full Range 0 to 48.3 | Hours | |
| Time in Direct Sunlight Between 10:00-15:00 on Pain-free Days | Placebo | 0.75 | Full Range 0 to 71.3 | Hours | |
| Maximum Severity of Phototoxic Reaction Experienced by Participants | Afamelanotide | 5.0 | Full Range 0 to 8 | score on a scale | |
| Maximum Severity of Phototoxic Reaction Experienced by Participants | Placebo | 5.0 | Full Range 0 to 10 | score on a scale | |
| Quality of Life Measured by Participant Completed Questionnaire | Afamelanotide | Day 0 | 34.7 | Full Range 3 to 67 | units on a scale |
| Quality of Life Measured by Participant Completed Questionnaire | Placebo | Day 0 | 22.2 | Full Range 3 to 78 | units on a scale |
| Quality of Life Measured by Participant Completed Questionnaire | Afamelanotide | Day 60 | 73.6 | Full Range 17 to 100 | units on a scale |
| Quality of Life Measured by Participant Completed Questionnaire | Placebo | Day 60 | 44.4 | Full Range 6 to 94 | units on a scale |
| Quality of Life Measured by Participant Completed Questionnaire | Afamelanotide | Day 120 | 84.7 | Full Range 6 to 100 | units on a scale |
| Quality of Life Measured by Participant Completed Questionnaire | Placebo | Day 120 | 55.6 | Full Range 6 to 100 | units on a scale |
| Quality of Life Measured by Participant Completed Questionnaire | Afamelanotide | Day 180 | 88.9 | Full Range 56 to 100 | units on a scale |
| Quality of Life Measured by Participant Completed Questionnaire | Placebo | Day 180 | 63.9 | Full Range 0 to 100 | units on a scale |
| Change of Total Protoporphyrin IX Level in Participants | Afamelanotide | Day 60 | -471.3 | Standard Deviation 505.4 | mcg/dL |
| Change of Total Protoporphyrin IX Level in Participants | Placebo | Day 60 | -628.5 | Standard Deviation 837.5 | mcg/dL |
| Change of Total Protoporphyrin IX Level in Participants | Afamelanotide | Day 120 | -511.8 | Standard Deviation 595.3 | mcg/dL |
| Change of Total Protoporphyrin IX Level in Participants | Placebo | Day 120 | -619.9 | Standard Deviation 1022.3 | mcg/dL |
| Change of Total Protoporphyrin IX Level in Participants | Afamelanotide | Day 180 | -92.7 | Standard Deviation 549.1 | mcg/dL |
| Change of Total Protoporphyrin IX Level in Participants | Placebo | Day 180 | -369.2 | Standard Deviation 1265.6 | mcg/dL |
| Number of Participants With Phototoxic Reactions With Likert Severity Scores ≥ 4 and ≥ 7 | Afamelanotide | Severity Likert score of ≥ 4 | 26 | Count of Participants | |
| Number of Participants With Phototoxic Reactions With Likert Severity Scores ≥ 4 and ≥ 7 | Placebo | Severity Likert score of ≥ 4 | 24 | Count of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01097044/results